Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNU7-2P is classified as a **pseudogene** of the U7 small nuclear RNA gene. Pseudogenes are genomic DNA sequences similar to normal genes but are non-functional; they typically arise from duplication or retrotransposition events. The functional U7 small nuclear RNA is a component of the U7 snRNP complex involved in the 3'-end processing of replication-dependent histone pre-mRNA, a process critical for histone biosynthesis and, indirectly, DNA replication and cell proliferation[1][4][5]. However, as a pseudogene, RNU7-2P itself is not transcribed into a functional product and does not perform any known biological role or serve as a therapeutic target. RNU7-2P may be referenced in genomic studies and annotated in gene databases, but it lacks established function, disease association, or drug interactions[1][5]. **Key context:** - RNU7-2P is distinct from the functional U7 snRNA gene (RNU7-1 or RNU7) that is essential for histone mRNA processing[4]. - There are several U7 snRNA pseudogenes described in the human genome, but none are known to have a biological function[1][4][5]. - The functional U7 snRNA is minimally 57–70 nucleotides long, forms part of the U7 snRNP, and is critical for a specific pre-mRNA processing step unique to metazoan histone genes[4]. Pseudogenes such as RNU7-2P do not participate in this process. **Problem/limitation with this entry:** - **RNU7-2P is not a protein, enzyme, receptor, or any classical molecular therapeutic target;** it is a non-functional pseudogene for a small nuclear RNA. Therefore, it would not have expected molecular function, disease associations, nor drug interactions and should not be considered a therapeutic target[1][5]. - Databases may list variants of these pseudogenes, but most do not express stable or functional RNA products[4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U7 small nuclear 2 pseudogene (RNU7-2P).